Astellas' Anemia Drug Roxadustat Shows Non-Inferiority to Amgen's Aranesp

Astellas Pharma, based in Tokyo, released the results from the Phase III DOLOMITES trial comparing its roxadustat with Amgen’s Aranesp (darbepoetin alfa) for anemia in non-dialysis dependent (NDD) adults with stage 3-5 chronic kidney disease (CKD).